Cordeiro Quirino, Miguita Karen, Miracca Elisabete, Elkis Hélio, Vallada Homero
Sao Paulo Med J. 2006 May 4;124(3):165-7. doi: 10.1590/s1516-31802006000300013.
Typical antipsychotics have a high affinity for dopamine receptors. It is therefore of interest to investigate such loci in pharmacogenetic studies on psychosis. We investigated the hypothesis that Ser9Gly polymorphism of the DRD3 gene may play a role in the differences in individual response to typical antipsychotics between schizophrenic patients. The sample was composed of 53 good responders and 59 poor ones. No significant differences between the good and poor responders were found in the allelic distribution (good responders: Ser9 61.32%, Gly9 38.67%; poor responders: Ser9 64.40%, Gly9 35.59%; odds ratio, OR = 0.88, 0.49 < OR < 1.56; chi2 = 0.23, 1 degree of freedom, df, p = 0.63) and genotype distribution (good responders: Ser9/Ser9 37.73%, Ser9/Gly9 47.16%, Gly9/Gly9 15.09%; poor responders: Ser9/Ser9 42.37%, Ser9/Gly9 44.06%, Gly9/Gly9 13.55%; chi2 = 0.25, 2 df, p = 0.88). Nor was there any association with homozygosity (good responders: homozygous: 52.82%, heterozygous: 47.16%; poor responders: homozygous: 55.92%, heterozygous: 44.06%; odds ratio, OR = 0.88, 0.39 < OR < 1.99; chi2 = 0.11, 1 df, p = 0.74). The results did not support the hypothesis that Ser9Gly polymorphism of the DRD3 gene influences the response to typical antipsychotics in our sample of schizophrenics.
典型抗精神病药物对多巴胺受体具有高亲和力。因此，在精神病的药物遗传学研究中研究此类基因座很有意义。我们研究了以下假设：DRD3基因的Ser9Gly多态性可能在精神分裂症患者对典型抗精神病药物的个体反应差异中起作用。样本由53名疗效良好者和59名疗效不佳者组成。疗效良好者和疗效不佳者在等位基因分布（疗效良好者：Ser9 61.32%，Gly9 38.67%；疗效不佳者：Ser9 64.40%，Gly9 35.59%；优势比，OR = 0.88，0.49 < OR < 1.56；卡方值 = 0.23，自由度df = 1，p = 0.63）和基因型分布（疗效良好者：Ser9/Ser9 37.73%，Ser9/Gly9 47.16%，Gly9/Gly9 15.09%；疗效不佳者：Ser9/Ser9 42.37%，Ser9/Gly9 44.06%，Gly9/Gly9 13.55%；卡方值 = 0.25，自由度df = 2，p = 0.88）方面未发现显著差异。与纯合性也无关联（疗效良好者：纯合子：52.82%，杂合子：47.16%；疗效不佳者：纯合子：55.92%，杂合子：44.06%；优势比，OR = 0.88，0.39 < OR < 1.99；卡方值 = 0.11，自由度df = 1，p = 0.74）。结果不支持DRD3基因的Ser9Gly多态性影响我们样本中精神分裂症患者对典型抗精神病药物反应的假设。
